-

Agilent Announces Full Workflow for US EPA Method 1633 for Targeted PFAS Analysis

Streamlined analysis of 40 PFAS compounds in wastewater and soil

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) announced today a highly-anticipated, complete workflow solution for targeted per- and polyfluoroalkyl substances (PFAS) analysis using the United States (US) Environmental Protection Agency (EPA) Method 1633 (3rd draft). EPA Draft Method 1633 currently analyzes 40 PFAS compounds in wastewater and soil and is a complex and labor-intensive method, relying on multiple sample preparation and analysis steps. Success in running the technique depends on careful sample handling and the appropriate sample preparation supplies and instrumentation.

The new workflow synchronizes with the recent launch of the Agilent 6495 Triple Quadrupole LC/MS (LC/TQ) system along with specific PFAS consumables, including the Agilent Bond Elut PFAS WAX Solid Phase Extraction (SPE) Cartridges, that provide the best recoveries while eliminating PFAS contamination and background, as well as the Agilent Infinity Lab PFC-free HPLC conversion kit, ‘PFAS-free’ Agilent vials and caps and other consumables. Specific data reporting needs for EPA 1633 are addressed through Agilent’s MassHunter Software, and sample tracking of the entire workflow can be done using the Agilent SLIMS Lab Management Platform enabling automation in data review and sample tracking which increases efficiency.

“PFAS are persistent, bioaccumulative, and of concern globally, with several countries looking to regulate them in water and soil. As a market leader in environmental analysis, Agilent is pleased to offer our customers a solution to achieve EPA Method 1633 performance requirements confidently,” explained Ken Suzuki, vice president and general manager of Agilent’s Mass Spectrometry Division. “This new workflow simplifies setup and provides a robust end-to-end analytical methodology that reduces method development time, increases throughput and accuracy, allowing customers to focus on running critical samples.”

Agilent’s Bond Elut PFAS WAX SPE Cartridges are explicitly designed for PFAS analysis, providing excellent extraction performance and flow rates for a broad range of PFAS compounds while complying with stringent regulatory requirements. The cartridges undergo PFAS-specific QC testing to ensure optimal cleanliness and recovery, so customers can confidently isolate PFAS from environmental matrices, such as wastewater and soil.

SLIMS simplifies the intake of analytical requests and streamlines task management. Connected to the 6495 LC/TQ SLIMS guides users through the workflow and ensures the instrument, consumables, and reagents are fit for purpose. MassHunter software generates specific instrument data reports passing the information to SLIMS for evaluation of results and creation of the certificate of analysis.

About Agilent Technologies

Agilent Technologies Inc. (NYSE: A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innovation that help our customers bring great science to life. Agilent’s full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers' most challenging questions. The company generated revenue of $6.85 billion in fiscal 2022 and employs 18,000 people worldwide. Information about Agilent is available at www.agilent.com. To receive the latest Agilent news, please subscribe to the Agilent Newsroom. Follow Agilent on LinkedIn and Facebook.

Contacts

MEDIA CONTACT
Naomi Goumillout
Agilent Technologies, Inc.
+1.781.266.2819
naomi.goumillout@agilent.com

AGILENT TECHNOLOGIES INC

NYSE:A
Details
Headquarters: Santa Clara, California, USA
CEO: Padraig McDonnell
Employees: 18000
Organization: PUB

Release Versions

Contacts

MEDIA CONTACT
Naomi Goumillout
Agilent Technologies, Inc.
+1.781.266.2819
naomi.goumillout@agilent.com

More News From AGILENT TECHNOLOGIES INC

Agilent Receives European IVDR Certification for Companion Diagnostic Assay in Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced its PD-L1 IHC 22C3 pharmDx (Code SK006) assay has received European IVDR certification for the use as a Companion Diagnostic (CDx) to aid in the identification of gastric or gastroesophageal Junction (GEJ) adenocarcinoma patients who may be eligible for treatment with KEYTRUDA® (pembrolizumab)1. PD-L1 IHC 22C3 pharmDx (Code SK006) is approved for exclusive use with the Agilent Autostainer Link 48 advanced...

Agilent to Announce Second-Quarter Fiscal Year 2025 Financial Results on May 28

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) will release financial results for the second quarter of fiscal year 2025 after the stock market closes on Wednesday, May 28. In addition, the company will host a conference call to discuss the results at 1:30 p.m. PDT on the same day. To join the listen-only conference call webcast, click the link on the Events section of Agilent’s investor relations website. A recording of the call also will be available on the website...

Agilent xCELLigence RTCA Instrumentation Applied in Recent FDA Approval

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) is pleased to announce its role in supporting Autolus Therapeutics’ FDA approval for AUCATZYL®, a recently approved CAR T therapy. Agilent's advanced cell analysis instrumentation, specifically the xCELLigence Real-Time Cell Analysis (RTCA) technology, was applied in developing and validating AUCATZYL. The xCELLigence RTCA technology supported the development and implementation of the potency assay. By providing precise a...
Back to Newsroom
  1. There was an issue with the authorization server. Please contact support if the issue persists.